ObsEva SA (OBSV)’s Financial Results Comparing With Arcturus Therapeutics Ltd. (NASDAQ:ARCT)

Both ObsEva SA (NASDAQ:OBSV) and Arcturus Therapeutics Ltd. (NASDAQ:ARCT) are Biotechnology companies, competing one another. We will compare their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ObsEva SA N/A 37958.30 76.72M -1.95 0.00
Arcturus Therapeutics Ltd. 10.20M 5.17 26.05M -4.19 0.00

We can see in table 1 the earnings per share, gross revenue and valuation of ObsEva SA and Arcturus Therapeutics Ltd.

Profitability

Table 2 provides us the return on equity, return on assets and net margins of both companies.

Net Margins Return on Equity Return on Assets
ObsEva SA 0.00% -51.7% -46.9%
Arcturus Therapeutics Ltd. -255.39% 0% 0%

Liquidity

ObsEva SA has a Current Ratio of 12.1 and a Quick Ratio of 12.1. Competitively, Arcturus Therapeutics Ltd.’s Current Ratio is 2.5 and has 2.5 Quick Ratio. ObsEva SA’s better ability to pay short and long-term obligations than Arcturus Therapeutics Ltd.

Insider and Institutional Ownership

Roughly 77.3% of ObsEva SA shares are owned by institutional investors while 14.6% of Arcturus Therapeutics Ltd. are owned by institutional investors. 15.19% are ObsEva SA’s share owned by insiders. Comparatively, Arcturus Therapeutics Ltd. has 23.9% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ObsEva SA 2.37% 2.29% -8.8% 0.39% -8.86% 2.37%
Arcturus Therapeutics Ltd. 3.88% 1.8% -16.69% -36.69% -7.96% 12.36%

For the past year ObsEva SA’s stock price has smaller growth than Arcturus Therapeutics Ltd.

Summary

Arcturus Therapeutics Ltd. beats on 5 of the 9 factors ObsEva SA.

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. The company intends to develop products for treating endometriosis, uterine fibroids, and preterm labor, as well as for enhancing clinical pregnancy and live birth rates in women undergoing IVF. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to improve clinical pregnancy and live birth rates in women undergoing IVF; and OBE022, an oral and selective prostaglandin F2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of pregnancy. The company was founded in 2012 and is headquartered in Plan-les-Ouates, Switzerland.

Arcturus Therapeutics Ltd. operates as an RNA medicines company. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 120 patents and patent applications issued in the United States, Europe, Japan, China, and other countries. Its proprietary UNA technology is used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes. The company develops novel RNA therapeutics through its partnerships with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, Synthetic Genomics Inc., and Cystic Fibrosis Foundation Therapeutics Inc. Arcturus Therapeutics Ltd. has a strategic collaboration with CureVac AG to jointly discover, develop, and commercialize novel messenger RNA therapeutics. The company was founded in 2013 and is headquartered in San Diego, California.